For the study, 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, were used to test the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.
Melittin can be produced synthetically, if further studies show it is viable. For the study, the bees were put to sleep with carbon dioxide and kept on ice before the venom barb was pulled out from the abdomen of the bee and the venom extracted by dissection. There are over 20,000 species of bees, no exact number is known, but this work also compared the effects of Perth honeybee venom to other honeybee populations in Ireland and England, as well as to the venom of bumblebees. The European honeybee in Australia, Ireland and England produced almost identical effects in breast cancer compared to normal cells. However, bumblebee venom was unable to induce cell death even at very high concentrations.
Dr. Ciara Duffy. Image: Harry Perkins Institute of Medical Research
A specific concentration of honeybee venom can induce 100% cancer cell death, while having minimal effects on normal cells, and melittin can completely destroy cancer cell membranes within 60 minutes.
Melittin in honeybee venom had another effect; within 20 minutes, melittin was able to substantially reduce the chemical messages of cancer cells that are essential to cancer cell growth and cell division.
"We looked at how honeybee venom and melittin affect the cancer signalling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signalling pathways were shut down," said Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research. "Melittin modulated the signalling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer."
- BCL11A: Novel Breast Cancer Gene Found
- New Compound Shows Potential For Triple-negative Breast Cancer
- ID4 Gene Switch Might Tame Triple Negative Breast Cancers
- Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent Of The Total Breast Cancer Drug Market In 2017
- A Chink In The Armor Of Breast Cancer Cells